ERLOTINIB FOR JAPANESE PATIENTS WITH RELAPSED SQUAMOUS CELL CARCINOMA OF THE LUNG

被引：0
|
作者：
Hata, Akito
Kei, Kunimasa
Hiroshige, Yoshioka
Shiro, Fujita
Reiko, Kaji
Ryo, Tachikawa
Keisuke, Tomii
Tadashi, Ishida
Nobuyuki, Katakami
机构：
来源：
RESPIROLOGY | 2010年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：71 / 71
页数：1
相关论文
共 50 条
  • [21] Erlotinib for the treatment of relapsed non-small cell lung cancer
    McLeod, C.
    Bagust, A.
    Boland, A.
    Hockenhull, J.
    Dundar, Y.
    Proudlove, C.
    Davis, H.
    Green, J.
    Macbeth, F.
    Stevenson, J.
    Walley, T.
    Dickson, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 41 - 47
  • [22] Afatinib and Erlotinib in the treatment of squamous-cell lung cancer
    Tagliamento, Marco
    Genova, Carlo
    Rijavec, Erika
    Rossi, Giovanni
    Biello, Federica
    Dal Bello, Maria Giovanna
    Alama, Angela
    Coco, Simona
    Boccardo, Simona
    Grossi, Francesco
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (18) : 2055 - 2062
  • [23] Metastatic cutaneous squamous cell carcinoma responding to erlotinib therapy
    Engelhardt, Candace
    Curiel-Lewandrowski, Clara
    Warneke, James
    Cranmer, Lee
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 65 (01) : 237 - 238
  • [24] Real-world efficacy of afatinib versus erlotinib in treating advanced squamous cell carcinoma of the lung
    Lee, Po-Hsin
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    RESPIROLOGY, 2023, 28 : 298 - 299
  • [25] Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers
    Felip, Enriqueta
    Soria, Jean-Charles
    Cobo, Manuel
    Lu, Shun
    Syrigos, Kostas
    Lee, Ki Hyeong
    Goker, Erdem
    Georgoulias, Vassilis
    Li, Wei
    Guclu, Salih
    Isla, Dolores
    Min, Young Joo
    Morabito, Alessandro
    Ardizzoni, Andrea
    Gadgeel, Shirish
    Dupuis, Nicholas
    Gibson, Neil
    Kraemer, Nicole
    Buehnemann, Claudia
    Solca, Flavio
    Ehrnrooth, Eva
    Goss, Glenwood
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1186 - S1187
  • [26] Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers
    Lee, K. H.
    Soria, J-C.
    Felip, E.
    Cobo, M.
    Lu, S.
    Syrigos, K.
    Goker, E.
    Georgoulias, V.
    Li, W.
    Guclu, S.
    Isla, D.
    Ardizzoni, A.
    Gadgeel, S. M.
    Dupuis, N.
    Gibson, N. J.
    Kramer, N.
    Buehnemann, C.
    Solca, F.
    Ehrnrooth, E.
    Goss, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] The prognostic value of morphologic findings carcinoma patients for lung squamous cell carcinoma patients
    Gurel, Duygu
    Ulukus, Cagnur
    Karacam, Volkan
    Ellidokuz, Hulya
    Umay, Cenk
    Oztop, Ilhan
    Sarioglu, Sulen
    PATHOLOGY RESEARCH AND PRACTICE, 2016, 212 (01) : 1 - 9
  • [28] Metabolomic analysis of the saliva of Japanese patients with oral squamous cell carcinoma
    Ohshima, Mitsuyoshi
    Sugahara, Keisuke
    Kasahara, Kiyohiro
    Katakura, Akira
    ONCOLOGY REPORTS, 2017, 37 (05) : 2727 - 2734
  • [29] Retrospective study of erlotinib in patients with advanced squamous lung cancer
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Chen, Hsuan-Yu
    Chang, Gee-Chen
    LUNG CANCER, 2012, 77 (01) : 128 - 133
  • [30] Serum proteomic analysis of lung squamous cell carcinoma patients
    Kuribayashi, Hidehiko
    Seike, Masahiro
    Okano, Tetsuya
    Soeno, Chie
    Yoshimura, Akinobu
    Kudoh, Shoji
    Gemma, Akihiko
    CANCER RESEARCH, 2009, 69
12345